Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,010 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90. Following the completion of the sale, the insider owned 133,633 shares in the company, valued at $34,810,060.17. The trade was a 0.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.

Natera Stock Performance

NASDAQ:NTRA opened at $253.82 on Thursday. The stock has a 50-day simple moving average of $244.16 and a 200-day simple moving average of $221.65. The stock has a market cap of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
• Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of the business. Reflection Asset Management purchased a new stake in Natera in the 4th quarter valued at $29,000. Elevation Wealth Partners LLC purchased a new stake in shares of Natera in the second quarter valued at about $30,000. Palladiem LLC purchased a new stake in shares of Natera in the fourth quarter valued at about $31,000. Horizon Investments LLC acquired a new stake in shares of Natera during the third quarter worth about $32,000. Finally, International Assets Investment Management LLC boosted its stake in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after buying an additional 97 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NTRA shares. William Blair initiated coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. Wolfe Research assumed coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price on the stock. Finally, Piper Sandler reiterated an “overweight” rating and set a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.